Business Context and Reporting Period
This Form 8-K is a current report filed by Eyenovia, Inc. (trading symbol: EYEN) on October 25, 2021. The filing provides preliminary financial updates for the period ended September 30, 2021, and announces a significant regulatory development regarding the company's lead product candidate, MydCombi.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $21.4 million as of September 30, 2021 (unaudited and preliminary).
- Outstanding Shares: Estimated at 25,963,185 shares of common stock as of September 30, 2021.
- Liquidity Outlook: Management believes existing cash and available credit will support operations into the first quarter of 2023.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the quarter or year-to-date.
- Debt: The filing mentions "available credit" but does not specify outstanding debt balances.
Material Changes and Regulatory Events
The primary material event reported is the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on October 22, 2021, regarding the New Drug Application (NDA) for MydCombi.
- Reclassification: The FDA reclassified MydCombi (a combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation) as a drug-device combination product.
- Company Response: Eyenovia is preparing necessary documents for an expedited resubmission of the NDA in response to the CRL.
Guidance, Outlook, and Risks
Management projects that current liquidity is sufficient to fund operations through Q1 2023. However, the filing includes standard forward-looking statement disclaimers regarding future expectations, cash needs, and the resubmission timeline for MydCombi.
Risks and Contingencies:
- The financial data presented is unaudited and preliminary; final results may differ upon completion of the review by management and the independent registered public accounting firm.
- Forward-looking statements are subject to risks detailed in the company's Form 10-K and Form 10-Q filings, including uncertainties related to regulatory approvals and clinical development.
Investor Verification Checklist
- Verify the final audited cash balance and share count in the upcoming Form 10-Q for the quarter ended September 30, 2021.
- Review the full text of the FDA Complete Response Letter (CRL) to understand specific requirements for the drug-device combination reclassification.
- Monitor the timeline for the expedited resubmission of the MydCombi NDA.
- Assess the company's burn rate and capital requirements to confirm the runway into Q1 2023 remains valid.